住院期间肠道菌群组成与重型COVID-19后60天死亡率相关
该研究基于挪威SARS-CoV2队列,在入院48小时内采集直肠拭子(基线n=123),三个月后复查(n=50),用16S rRNA基因测序分析肠道菌群。基线菌群Shannon指数在需ICU治疗的患者中低于普通病房患者;代表ICU与病房患者菌群失衡的失调指数与ICU入住独立相关(校正p<0.001),并与全身炎症相关。该失调指数与60天死亡率相关(单变量HR 3.70 [2.00-8.6],p<0.001),分别校正协变量后仍相关;三个月随访时ICU患者失调指数仍高于病房患者(校正p=0.007)。作者认为因临床终点少,数据属探索性,提示住院期间肠道菌群改变可能与重型COVID-19不良预后相关,需更大型研究。
要点
- 入院48小时内粪便菌群失调指数(ICU较病房富集与减少菌群的平衡)与需ICU入住独立相关(校正p<0.001)。
- 该失调指数与60天死亡率相关:单变量HR 3.70(95%CI 2.00-8.6),p<0.001,分别校正协变量后仍相关。
- 基线Shannon多样性指数在需ICU的COVID-19患者中低于普通病房患者。
- 失调指数包括产丁酸菌丰度下降和部分口腔菌群富集,并与全身炎症相关。
- 三个月随访时ICU患者失调指数仍高于病房患者(校正p=0.007);作者称数据为探索性。
适用人群与场景
- 纳入挪威SARS-CoV2队列研究的住院COVID-19患者,入院48小时内采集直肠拭子(基线n=123),三个月后复查(n=50)。
- 比较住院期间需ICU治疗与普通病房管理的患者。
研究设计与关键结果
- 研究类型:挪威SARS-CoV2队列研究子集,基线n=123、三个月随访n=50,直肠拭子16S rRNA基因测序。
- 基线Shannon指数在需ICU入院的COVID-19患者中低于普通病房患者。
- 失调指数(ICU较病房富集与减少菌群的平衡,包括产丁酸菌丰度下降和部分口腔菌群富集)与需ICU入住独立相关,校正抗生素使用、地塞米松使用、慢性肺病、PO2/FiO2比值、C反应蛋白、中性粒细胞计数或肌酐水平后校正p<0.001。
- 基线失调指数与全身炎症相关,并与60天死亡率相关:单变量HR 3.70(95%CI 2.00-8.6),p<0.001;分别校正协变量后仍相关。
- 三个月随访时失调指数在ICU患者中仍高于病房患者(校正p=0.007)。
证据类型、等级与局限
- 证据类型:队列研究(挪威SARS-CoV2队列研究子集)。
- 作者称数据应视为探索性,因临床终点数量少。
- 局限:临床终点数量少(原文称低数量临床终点);作者认为需更大型研究探讨COVID-19肠道受累与长期临床结局的关系。
对床旁实践的改变
- 作者认为住院期间肠道菌群改变可能与重型COVID-19不良预后相关,但因数据为探索性,尚不能据此改变床旁实践。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Gut microbiota alterations have been reported in hospitalized COVID-19 patients, with reduced alpha diversity and altered microbiota composition related to respiratory failure. However, data regarding gut microbiota and mortality are scarce.
METHODS: Rectal swabs for gut microbiota analyses were collected within 48 h after hospital admission (baseline; n = 123) and three-month post-admission (n = 50) in a subset of patients included in the Norwegian SARS-CoV2 cohort study. Samples were analysed by sequencing the 16S rRNA gene. Gut microbiota diversity and composition at baseline were assessed in relation to need for intensive care unit (ICU) admission during hospitalization. The primary objective was to investigate whether the ICU-related gut microbiota was associated with 60-day mortality.
RESULTS: Gut microbiota diversity (Shannon index) at baseline was lower in COVID-19 patients requiring ICU admission during hospitalization than in those managed in general wards. A dysbiosis index representing a balance of enriched and reduced taxa in ICU compared with ward patients, including decreased abundance of butyrate-producing microbes and enrichment of a partly oral bacterial flora, was associated with need of ICU admission independent of antibiotic use, dexamethasone use, chronic pulmonary disease, PO2/FiO2 ratio, C-reactive protein, neutrophil counts or creatinine levels (adjusted p < 0.001). The ICU-related dysbiosis index at baseline correlated with systemic inflammation and was associated with 60-day mortality in univariate analyses (Hazard ratio 3.70 [2.00-8.6], p < 0.001), as well as after separate adjustment for covariates. At the three-month follow-up, the dysbiosis index remained elevated in ICU patients compared with ward patients (adjusted p = 0.007).
CONCLUSIONS: Although our data should be regarded as exploratory due to low number of clinical end points, they suggest that gut microbiota alterations during hospitalization could be related to poor prognosis after severe COVID-19. Larger studies of gut involvement during COVID-19 in relation to long-term clinical outcome are warranted. Trial registration NCT04381819 . Retrospectively registered May 11, 2020.
参考来源
- Trøseid M, Holter JC, Holm K, et al. Gut microbiota composition during hospitalization is associated with 60-day mortality after severe COVID-19. Crit Care. 2023. PMID: 36814280. doi:10.1186/s13054-023-04356-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。